Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
A phase 3 trial of Pembrolizumab, Epacadostat, Sunitinib and Pazopanib in Renal cell carcinoma, run by Incyte Corporation, completed.
Overview
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) is a phase 3 interventional study registered as NCT03260894 by Incyte Corporation, with 129 participants recorded, started 2017-12-07 and reaching its primary completion in 2018-08-22. Interventions recorded: Pembrolizumab, Epacadostat, Sunitinib, Pazopanib. Conditions recorded: Renal Cell Carcinoma (RCC).
Linked to the drug Epacadostat because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialPembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Shares Epacadostat, Incyte, Pembrolizumab and the tag pipeline.
- TrialNivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Shares Epacadostat, Incyte and the tag pipeline.
- TrialA Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Shares Incyte and the tag pipeline.
- TrialA Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Shares Sunitinib, Renal cell carcinoma and the tag pipeline.
- TrialSavolitinib vs. Sunitinib in MET-driven PRCC.
Shares Sunitinib, Renal cell carcinoma and the tag pipeline.
- TrialSubstudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Shares Renal cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialSubstudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Shares Renal cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialModi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Shares Renal cell carcinoma, Pembrolizumab and the tag pipeline.